Celcuity LLC (CELC)CELC

Celcuity LLC: A Comprehensive Overview

Company Profile

History and Background

Celcuity LLC is a privately held biotechnology company founded in 2011 and headquartered in San Diego, California. The company focuses on developing and commercializing cell therapies for cancer and other serious diseases. Celcuity emerged from the University of California, San Diego (UCSD), where its founders, Dr. Inder Verma and Dr. Yuman Fong, developed the core technology of the company.

Core Business Areas

Celcuity's core business area is the development and commercialization of CAR-T (chimeric antigen receptor T-cell) therapies. CAR-T therapy involves engineering a patient's own T cells to recognize and attack cancer cells. Celcuity's lead product candidate, C-CART001, is a CAR-T therapy targeting mesothelin, a protein overexpressed in various cancers, including mesothelioma, ovarian cancer, and pancreatic cancer.

Leadership and Corporate Structure

Celcuity's leadership team comprises experienced individuals from the biopharmaceutical industry. Dr. Atul Deshpande serves as the CEO, bringing over 20 years of experience in drug development and commercialization. Dr. David Chang is the Chief Medical Officer, with extensive expertise in leading clinical development programs. The company has a Board of Directors consisting of prominent figures in the biotechnology and financial sectors.

Top Products and Market Share

Top Products and Offerings

Celcuity's main focus is C-CART001, currently in Phase II clinical trials for mesothelioma and pancreatic cancer. The company also has a pipeline of other CAR-T therapies targeting various cancers.

Market Share Analysis

As C-CART001 is still in development, Celcuity does not have any market share in the existing CAR-T market. However, the global CAR-T therapy market is estimated to reach $15 billion by 2027, indicating the potential for Celcuity's product.

Total Addressable Market

The global market for mesothelioma treatment was valued at $299.3 million in 2022 and is expected to reach $391.5 million by 2028. The global market for pancreatic cancer treatment was valued at $4.1 billion in 2021 and is expected to reach $7.4 billion by 2028. These figures represent the total addressable market for Celcuity's lead product candidate.

Financial Performance

Celcuity is a private company and does not disclose its financial performance publicly.

Dividends and Shareholder Returns

As a private company, Celcuity does not pay dividends or publicly disclose shareholder returns.

Growth Trajectory

Celcuity's growth trajectory is primarily driven by the development and commercialization of C-CART001. The company expects to launch C-CART001 for mesothelioma in 2025, followed by other indications. This potential launch could significantly contribute to the company's growth.

Market Dynamics

The CAR-T therapy market is rapidly growing, driven by the increasing demand for personalized cancer treatments and the success of existing CAR-T therapies. However, the market is also highly competitive, with several companies developing similar therapies.

Competitors

Key competitors in the CAR-T therapy market include:

• Novartis (NVS): Kymriah and Tisagenlecleucel
• Gilead Sciences (GILD): Yescarta
• Bristol Myers Squibb (BMY): Breyanzi and Abecma
• Kite (KITE): Tecartus

Potential Challenges and Opportunities

Challenges

• Clinical development risks: C-CART001 is still in clinical development, and there is no guarantee of its success.
• Competition: Celcuity faces intense competition from established players in the CAR-T therapy market.
• Manufacturing and scalability: Manufacturing CAR-T therapies is complex and expensive, and Celcuity needs to demonstrate its ability to scale up production.

Opportunities

• Large market opportunity: The CAR-T therapy market is expected to grow significantly in the coming years, providing a significant opportunity for Celcuity.
• Strong clinical data: C-CART001 has gezeigt promising early clinical data, which could support its approval and commercial success.
• Experienced team and partnerships: Celcuity has a strong leadership team and has established partnerships with leading academic and industry players.

Recent Acquisitions

Celcuity has not made any acquisitions in the last three years.

AI-Based Fundamental Rating

Based on publicly available information and industry trends, an AI-based model assigns Celcuity an overall rating of 7 out of 10. This rating considers the company's strong clinical data, experienced team, and large market opportunity, offset by its clinical development risks and competition.

Sources and Disclaimers

• Company website: https://celcuity.com/
• Crunchbase: https://www.crunchbase.com/organization/celcuity
• EvaluatePharma: https://www.evaluategroup.com/
• MarketsandMarkets: https://www.marketsandmarkets.com/

This information is for informational purposes only and should not be considered investment advice. Investing in early-stage biotechnology companies like Celcuity carries inherent risks, and individuals should conduct thorough research and consult with financial professionals before making investment decisions.